Abstract 152P
Background
Nanoliposomal irinotecan with fluorouracil and folinic acid (Nal-IRI/FU/LV; NFF) is a standard treatment after gemcitabine-based chemotherapy for unresectable pancreatic cancer (uPC) patients (pts). However, there has been no data comparing safety between prior biliary drainage (BD) and non-BD (NBD). Therefore, we conducted such a study and report the results of the interim sub-analysis.
Methods
As part of a pre-planned interim analysis of a multicenter prospective observational study from June 2021, we analyzed the patient characteristics and clinical outcomes of uPC pts associated with safety; adverse events (AEs), dose modification, and relative dose intensity between patients in the BD and NBD groups. This analysis was conducted on attaining 50% of the target cases.
Results
The median follow-up period was 5.3 months. Of the 75 pts, NFF was administered to the 19 pts in the BD group and the 56 pts in the NBD group. The BD group was significantly younger (p=0.049), included more locally advanced disease (p=0.04) and pancreatic head cases (p<0.01), and the duration of their previous treatment was shorter (p=0.02) compared with the NBD group. The median relative dose intensities in the BD and NBD groups of Nal-IRI were 78.1% and 69.8% (p=0.21) and of FU 89.9% and 80.4% (p=0.23), respectively. For the initial dose, 42% and 59% of pts in the BD and NBD groups needed Nal-IRI dose reduction, respectively (p=0.53). The rates of dose reduction during NFF did not differ in Nal-IRI or in FU, and those of discontinuation of NFF due to AEs were similar in the two groups (7% vs 8%). The rate of grade 3/4 non-hematological AEs was higher in the BD group (63% vs 30%; p=0.01), whereas that of hematological AEs was equivalent (32% vs 32%; p=0.96). Frequent grade 3/4 AEs in the BD group were neutropenia (26%), anemia (16%), and fatigue (15%). Additionally, biliary tract infections were observed only in the BD group (16%, p<0.01).
Conclusions
NFF more frequently caused severe non-hematological AEs and biliary tract infections in the BD group. Therefore, more attention should be paid to pts with prior BD for safety.
Clinical trial identification
Editorial acknowledgement
We thank Robert Blakytny, DPhil, from Edanz for editing a draft of this abstract.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
143P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display
Resources:
Abstract
144P - Integrated clinical and genomic models using machine-learning methods to predict the efficacy of paclitaxel-based chemotherapy in patients with advanced gastric cancer from K-MASTER project
Presenter: Jwa Hoon Kim
Session: Poster Display
Resources:
Abstract
145P - Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)
Presenter: Longqi Chen
Session: Poster Display
Resources:
Abstract
146P - Phase (ph) Ib results of bemarituzumab (BEMA) added to capecitabine/oxaliplatin (CAPOX) or S-1/oxaliplatin (SOX) with or without nivolumab (NIVO) for previously untreated advanced gastric/gastroesophageal junction cancer (G/GEJC): FORTITUDE-103 study
Presenter: Keun-Wook Lee
Session: Poster Display
Resources:
Abstract
147P - Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
148P - Safety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR)
Presenter: Teiji Kuzuya
Session: Poster Display
Resources:
Abstract
149P - A prospective observational study of MSI screening in unresectable chemotherapy-naïve advanced gastric cancer/gastroesophageal junction cancer: WJOG13320GPS
Presenter: Yukiya Narita
Session: Poster Display
Resources:
Abstract
150P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
151P - Relationship between depth of response and early tumor shrinkage with overall survival in advanced pancreatic cancer
Presenter: EMIKA KUROKI
Session: Poster Display
Resources:
Abstract
153P - IMbrave150: Exploratory analyses for investigating associations between overall survival (OS) and depth of response (DpR) or duration of response (DoR) in patients (pts) with unresectable hepatocellular carcinoma (HCC)
Presenter: Masatoshi Kudo
Session: Poster Display
Resources:
Abstract